Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.94 million shs	N/A
HCM HUTCHMED	$17.27 -2.9%	$15.99	$11.51 ▼ $21.50	$3.10B	0.55	39,756 shs	45,952 shs
IMVT Immunovant	$15.71 -2.3%	$16.41	$12.72 ▼ $34.47	$2.75B	0.66	1.30 million shs	1.53 million shs
KYMR Kymera Therapeutics	$42.96 -1.8%	$43.85	$19.44 ▼ $53.27	$2.85B	2.18	557,010 shs	393,426 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMRX Chimerix	0.00%	0.00%	0.00%	0.00%	+859.98%
HCM HUTCHMED	-2.87%	-1.93%	+10.07%	+15.13%	-11.16%
IMVT Immunovant	-2.30%	-7.32%	-6.54%	-0.57%	-45.96%
KYMR Kymera Therapeutics	-1.81%	-6.18%	-3.53%	+21.77%	-7.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMRX Chimerix	0.8379 of 5 stars	1.0	0.0	4.1	0.0	1.7	0.6
HCM HUTCHMED	3.1802 of 5 stars	3.3	4.0	0.0	3.3	0.0	1.9
IMVT Immunovant	1.4287 of 5 stars	3.4	0.0	0.0	2.5	1.7	0.0
KYMR Kymera Therapeutics	3.5621 of 5 stars	4.6	3.0	0.0	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
HCM HUTCHMED	2.50	Moderate Buy	$28.00	62.13% Upside
IMVT Immunovant	2.82	Moderate Buy	$36.40	131.70% Upside
KYMR Kymera Therapeutics	3.10	Buy	$59.11	37.60% Upside

Current Analyst Ratings Breakdown

Latest CMRX, HCM, IMVT, and KYMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	KYMR Kymera Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$60.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/15/2025	KYMR Kymera Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/3/2025	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/27/2025	KYMR Kymera Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$56.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$59.00
6/26/2025	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$57.00 ➝ $53.00
6/26/2025	KYMR Kymera Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $60.00
6/25/2025	KYMR Kymera Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$64.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
HCM HUTCHMED	$630.20M	4.78	$0.28 per share	61.90	$4.43 per share	3.90
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KYMR Kymera Therapeutics	$47.07M	59.43	N/A	N/A	$12.90 per share	3.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	11.83	N/A	N/A	N/A	N/A	8/7/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
KYMR Kymera Therapeutics	-$223.86M	-$3.10	N/A	N/A	N/A	-409.07%	-30.11%	-25.65%	8/6/2025 (Estimated)

Latest CMRX, HCM, IMVT, and KYMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	KYMR Kymera Therapeutics	-$0.84	N/A	N/A	N/A	$17.37 million	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/9/2025	Q1 2025	KYMR Kymera Therapeutics	-$0.92	-$0.82	+$0.10	-$0.82	$11.38 million	$22.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMRX Chimerix	N/A	6.33	6.33
HCM HUTCHMED	0.08	2.83	2.70
IMVT Immunovant	N/A	11.16	11.16
KYMR Kymera Therapeutics	N/A	8.49	8.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMRX Chimerix	45.42%
HCM HUTCHMED	8.82%
IMVT Immunovant	47.08%
KYMR Kymera Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CMRX Chimerix	13.10%
HCM HUTCHMED	3.60%
IMVT Immunovant	1.80%
KYMR Kymera Therapeutics	16.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KYMR Kymera Therapeutics	170	65.12 million	54.69 million	Optionable

CMRX, HCM, IMVT, and KYMR Headlines

Recent News About These Companies

B. Riley Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR)

July 31 at 9:35 AM | marketbeat.com

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 30 at 11:06 AM | zacks.com

Kymera Therapeutics (KYMR) to Release Quarterly Earnings on Wednesday

July 30 at 5:13 AM | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 30 at 4:20 AM | marketbeat.com

Neo Ivy Capital Management Invests $395,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 27, 2025 | marketbeat.com

Jennison Associates LLC Sells 164,647 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

July 21, 2025 | marketbeat.com

Kymera Therapeutics (NASDAQ:KYMR) Upgraded at The Goldman Sachs Group

July 18, 2025 | marketbeat.com

Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?

July 18, 2025 | zacks.com

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts

July 17, 2025 | marketbeat.com

Kymera Therapeutics Inc (KYMR) - Investing.com

July 11, 2025 | investing.com

Q3 EPS Estimate for Kymera Therapeutics Raised by Analyst

July 9, 2025 | marketbeat.com

Kymera Therapeutics (KYMR) director group buys $13.9 million in stock

July 3, 2025 | investing.com

Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated at Morgan Stanley

July 3, 2025 | marketbeat.com

Tuesday’s Insider Activity: Major Buys and Sells Shake Up Markets

July 3, 2025 | investing.com

Insider Buying: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys 317,167 Shares of Stock

July 2, 2025 | insidertrades.com

Bros. Advisors Lp Baker Purchases 655,500 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

July 1, 2025 | insidertrades.com

Kymera Therapeutics Announces Pricing of $250 Million Public Offering

June 26, 2025 | globenewswire.com

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

June 26, 2025 | zacks.com

KYMR Kymera Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

Kymera signs $750M Gilead deal, announces $250M stock offering

June 26, 2025 | bizjournals.com

Kymera Therapeutics Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMRX, HCM, IMVT, and KYMR Company Descriptions

Chimerix NASDAQ:CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

HUTCHMED NASDAQ:HCM

$17.27 -0.51 (-2.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$17.23 -0.04 (-0.26%)

As of 08/1/2025 04:10 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Immunovant NASDAQ:IMVT

$15.71 -0.37 (-2.30%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$15.55 -0.16 (-1.02%)

As of 08/1/2025 07:33 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Kymera Therapeutics NASDAQ:KYMR

$42.96 -0.79 (-1.81%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$42.92 -0.04 (-0.09%)

As of 08/1/2025 04:04 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time